Craig-Hallum analyst Chase Knickerbocker raised the firm's price target on Celcuity to $189 from $141 and keeps a Buy rating on the shares following the company's announcement of statistically significant and clinically meaningful results for both the geda triplet and, notably, the doublet in the VIKTORIA-1 mutant cohort, ahead of a late-breaker PFS presentation at ASCO. The firm says significance in the unpowered doublet is highly encouraging and suggests strong efficacy, providing an important anchor point ahead of full PFS data and likely pulling forward some stock reaction.
